Cargando…

Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling

BACKGROUND: Tyrosine kinases drive the proliferation and survival of many human cancers. Thus profiling the global state of tyrosine phosphorylation of a tumor is likely to provide a wealth of information that can be used to classify tumors for prognosis and prediction. However, the comprehensive an...

Descripción completa

Detalles Bibliográficos
Autores principales: Machida, Kazuya, Eschrich, Steven, Li, Jiannong, Bai, Yun, Koomen, John, Mayer, Bruce J., Haura, Eric B.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957407/
https://www.ncbi.nlm.nih.gov/pubmed/20976048
http://dx.doi.org/10.1371/journal.pone.0013470
_version_ 1782188229021138944
author Machida, Kazuya
Eschrich, Steven
Li, Jiannong
Bai, Yun
Koomen, John
Mayer, Bruce J.
Haura, Eric B.
author_facet Machida, Kazuya
Eschrich, Steven
Li, Jiannong
Bai, Yun
Koomen, John
Mayer, Bruce J.
Haura, Eric B.
author_sort Machida, Kazuya
collection PubMed
description BACKGROUND: Tyrosine kinases drive the proliferation and survival of many human cancers. Thus profiling the global state of tyrosine phosphorylation of a tumor is likely to provide a wealth of information that can be used to classify tumors for prognosis and prediction. However, the comprehensive analysis of tyrosine phosphorylation of large numbers of human cancer specimens is technically challenging using current methods. METHODOLOGY/PRINCIPAL FINDINGS: We used a phosphoproteomic method termed SH2 profiling to characterize the global state of phosphotyrosine (pTyr) signaling in human lung cancer cell lines. This method quantifies the phosphorylated binding sites for SH2 domains, which are used by cells to respond to changes in pTyr during signaling. Cells could be grouped based on SH2 binding patterns, with some clusters correlated with EGF receptor (EGFR) or K-RAS mutation status. Binding of specific SH2 domains, most prominently RAS pathway activators Grb2 and ShcA, correlated with EGFR mutation and sensitivity to the EGFR inhibitor erlotinib. SH2 binding patterns also reflected MET activation and could identify cells driven by multiple kinases. The pTyr responses of cells treated with kinase inhibitors provided evidence of distinct mechanisms of inhibition. CONCLUSIONS/SIGNIFICANCE: This study illustrates the potential of modular protein domains and their proteomic binding profiles as powerful molecular diagnostic tools for tumor classification and biomarker identification.
format Text
id pubmed-2957407
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-29574072010-10-25 Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling Machida, Kazuya Eschrich, Steven Li, Jiannong Bai, Yun Koomen, John Mayer, Bruce J. Haura, Eric B. PLoS One Research Article BACKGROUND: Tyrosine kinases drive the proliferation and survival of many human cancers. Thus profiling the global state of tyrosine phosphorylation of a tumor is likely to provide a wealth of information that can be used to classify tumors for prognosis and prediction. However, the comprehensive analysis of tyrosine phosphorylation of large numbers of human cancer specimens is technically challenging using current methods. METHODOLOGY/PRINCIPAL FINDINGS: We used a phosphoproteomic method termed SH2 profiling to characterize the global state of phosphotyrosine (pTyr) signaling in human lung cancer cell lines. This method quantifies the phosphorylated binding sites for SH2 domains, which are used by cells to respond to changes in pTyr during signaling. Cells could be grouped based on SH2 binding patterns, with some clusters correlated with EGF receptor (EGFR) or K-RAS mutation status. Binding of specific SH2 domains, most prominently RAS pathway activators Grb2 and ShcA, correlated with EGFR mutation and sensitivity to the EGFR inhibitor erlotinib. SH2 binding patterns also reflected MET activation and could identify cells driven by multiple kinases. The pTyr responses of cells treated with kinase inhibitors provided evidence of distinct mechanisms of inhibition. CONCLUSIONS/SIGNIFICANCE: This study illustrates the potential of modular protein domains and their proteomic binding profiles as powerful molecular diagnostic tools for tumor classification and biomarker identification. Public Library of Science 2010-10-19 /pmc/articles/PMC2957407/ /pubmed/20976048 http://dx.doi.org/10.1371/journal.pone.0013470 Text en Machida et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Machida, Kazuya
Eschrich, Steven
Li, Jiannong
Bai, Yun
Koomen, John
Mayer, Bruce J.
Haura, Eric B.
Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling
title Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling
title_full Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling
title_fullStr Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling
title_full_unstemmed Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling
title_short Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling
title_sort characterizing tyrosine phosphorylation signaling in lung cancer using sh2 profiling
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957407/
https://www.ncbi.nlm.nih.gov/pubmed/20976048
http://dx.doi.org/10.1371/journal.pone.0013470
work_keys_str_mv AT machidakazuya characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling
AT eschrichsteven characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling
AT lijiannong characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling
AT baiyun characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling
AT koomenjohn characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling
AT mayerbrucej characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling
AT hauraericb characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling